# DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

> **NCT02035813** · PHASE2 · COMPLETED · sponsor: **Prof. Wolfgang Janni** · enrollment: 116 (actual)

## Conditions studied

- HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer
- HER2-negative Circulating Tumor Cells
- Postmenopausal Female Patients

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT02035813
- **Lead sponsor:** Prof. Wolfgang Janni
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2024-01-10
- **Final completion:** 2024-01-10
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035813, "DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02035813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*